Montevideo, May 07, 2025 (GLOBE NEWSWIRE) -- MercadoLibre, Inc. (Nasdaq: MELI) (http://www.mercadolibre.com) today reported financial results for the first quarter ended March 31, 2025, in a Letter to Shareholders, which is now posted to the company's Investor Relations website https://investor.mercadolibre.com. In order to access our video webcast and the live audio, investors, analysts and the market in general may access the following link at https://event.choruscall.com/mediaframe/webcast.html?webcastid ...

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionano.com Conference Call & Webcast Details CONTACTS | Date: | Wednesday, May 14, 2025 | | --- | --- | | Time: | 4:30 p.m ...

Exclusive community offers single-family homes with access to a robust selection of amenities in sought-after West Jordan Move-in ready and quick move-in homes with Designer Appointed Features are also available in the community. Quick move-in homes by Toll Brothers are already under construction, providing home shoppers with the opportunity to step inside their home and experience the floorplan, home site, and views first-hand. Customers also enjoy the luxury of having a home professionally designed from t ...

ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use. For Investor Inquiries: Anika Therapeutics, Inc. Matt Hall, 781-457-9554 Director, Corporate Development and Investor Relations investorrelations@anika.com Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika's website, www.anika.com. An archive of the presentation will also be available on the website ...

About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA-approved prescription drugs for dermatological conditions. The Journey Medical team comprises industry experts with extensive exp ...

CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (NASDAQ: MRCC) today announced its financial results for the first quarter ended March 31, 2025. Except where the context suggests otherwise, the terms "Company," "we," "us," and "our" refer to Monroe Capital Corporation (together with its subsidiaries). First Quarter 2025 Financial Highlights Chief Executive Officer Theodore L. Koenig commented, "We are pleased to announce that we paid a $0.25 per share dividend during the first quarter r ...

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs. Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today annou ...

MOUNTAIN VIEW, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- LegalZoom.com, Inc. (Nasdaq: LZ) today announced results for its first quarter ended March 31, 2025. "Our first quarter results reflect accelerating subscription growth and solid progress towards our goal of double- digit subscription revenue growth in the fourth quarter," said Jeff Stibel, Chairman and Chief Executive Officer of LegalZoom. "While no company is immune to today's volatile environment, our first quarter results exceeded our expectations ...

First Quarter 2025 Revenues of $302.6 Million Reflect 9.2 Percent Growth and 7.4 Percent Organic Growth Over First Quarter 2024 Revenues of $277.2 Million First Quarter 2025 Consolidated Book to Bill Ratio of 1.2 to 1 and Bookings of $365.6 Million Last Twelve Months Ended March 30, 2025 Consolidated Book to Bill Ratio of 1.2 to 1 and Bookings of $1.401 Billion SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National ...

Alex Braun abraun@acumenpharm.com NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. Media: AcumenPR@westwicke.com The live webc ...